Ukraine has procured 12,000 doses of PLX-R18, a medication intended for treating radiation sickness (acute radiation syndrome), from the Israeli biotechnology company Pluri. This acquisition was made in preparation for a potential nuclear threat.

This was reported by the Israeli ambassador to Ukraine, Michael Brodsky, via Telegram, citing The Times of Israel.

Preparedness for nuclear threats: Ukraine acquires PLX-R18 medication

The ambassador quoted the Israeli publication, stating that “the Israeli company Pluri has signed a contract with a Ukrainian umbilical cord blood bank for the supply of PLX-R18”. This medication aids in the recovery of platelets as well as red and white blood cells that are damaged by radiation exposure.

In total, Ukraine will receive sufficient doses to treat 6,000 individuals. It has been reported that the purchased medication will be stored as a reserve in case of a nuclear threat. If necessary, it will be quickly dispatched to hospitals across the country to assist affected individuals.

In March, Russian forces utilized chemical weapons against the Armed Forces of Ukraine nearly 770 times.

Earlier, the General Staff of the Armed Forces of Ukraine reported 767 instances of Russian troops using munitions containing hazardous chemical substances against Ukrainian defense forces in March 2025.

Since February 2023, when such attacks became systematic, 7,730 similar incidents have been recorded.

As of early March, since the beginning of the full-scale invasion of Ukraine, Russian forces have used munitions with toxic chemical compounds over 6,900 times.

In March 2024, the Ukrainian delegation at the OSCE urged the international community to respond to Russia's use of chemical weapons against Ukrainian defenders, not only through political condemnation.